Abstract

This study describes the effect of a biologic currently under development for the treatment of osteoarthritis to induce both cytoskeletal and transcriptional changes in bone marrow-derived mesenchymal stem cells. These changes may have implications for the regenerative potential of low molecular weight fraction of commercial 5% human serum albumin and could help explain some of the clinical findings in the clinical trials conducted using this drug.

Details

Title
Low Molecular Weight Fraction of Commercial Human Serum Albumin Induces Morphologic and Transcriptional Changes of Bone Marrow-Derived Mesenchymal Stem Cells
Author
Bar-Or, David 1 ; Thomas, Gregory W 2 ; Rael, Leonard T 2 ; Gersch, Elizabeth D 2 ; Rubinstein, Pablo 3 ; Brody, Edward 4 

 Swedish Medical Center, Trauma Research Department, Englewood, Colorado, USA; St. Anthony Hospital, Trauma Research Department, Lakewood, Colorado, USA; Medical Center of Plano, Trauma Research Department, Plano, Texas, USA; Ampio Pharmaceuticals Inc., Englewood, Colorado, USA 
 Swedish Medical Center, Trauma Research Department, Englewood, Colorado, USA; Ampio Pharmaceuticals Inc., Englewood, Colorado, USA 
 New York Blood Center, New York, New York, USA 
 SomaLogic Inc., Boulder, Colorado, USA 
Pages
945-955
Section
Tissue Engineering and Regenerative Medicine
Publication year
2015
Publication date
Aug 2015
Publisher
Oxford University Press
ISSN
21576564
e-ISSN
21576580
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
2299128709
Copyright
© 2015. This work is published under https://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.